Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Opsoclonus
Semin Neurol 16:21-26, Averbuch-Heller,L.&Remler,B., 1996
Nocturnal Blood Pressure Dip in Stroke Survivors, A Pilot Study
Stroke 26:1373-1378, Nakamura,K.,et al, 1995
Long-Term Safety of Azathioprine Therapy in Multiple Sclerosis
Neurol 43:831-833, Amato,M.P.,et al, 1993
Putaminal Hemorrhage:Clinical-Computed Tomographic Correlations
Neuroradiology 32:200-206, Weisberg,L.A.,et al, 1990
Intracerebral Hemorrhage & Phenylpropanolamine Use
Neurol 37:399-404, Kase,C.S.,et al, 1987
Pimozide Treatment of Tic & Tourette Disorders
Pediatrics 79:1032-1039, Shapiro,A.K.,et al, 1987
Opsoclonus in Adults
Arch Neurol 43:1165-1175, Digre,K.B., 1986
Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985
Taste & Smell in Disease (First of Two Parts)
NEJM 308:1275-1279, Schiffman,S.S., 1983
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979
Upbeat Nystagmus
JAMA 225:312, Daroff,R.B.,et al, 1973